-
1.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis 有权RNAi相关抑制TNFα信号通路治疗眼血管生成公开(公告)号：US08754202B2
公开(公告)日：2014-06-17
申请号：US13169549
申请日：2011-06-27
IPC分类号： C07H21/04
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。
-
公开(公告)号：US08618278B2
公开(公告)日：2013-12-31
申请号：US13493098
申请日：2012-06-11
IPC分类号： C07H21/04
CPC分类号： C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/141
摘要： RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
-
公开(公告)号：US08569258B2
公开(公告)日：2013-10-29
申请号：US13584256
申请日：2012-08-13
申请人： Jon E. Chatterton
发明人： Jon E. Chatterton
CPC分类号： A61K47/484 , A61K31/7088 , A61K31/713 , A61K38/16 , A61K47/64 , A61K47/6425 , A61K47/6455 , A61K47/6807 , A61K47/6849 , C07K16/28 , C07K2319/74 , C12N15/111 , C12N15/113 , C12N15/1138 , C12N2310/14 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2320/30 , C12N2320/32 , C12N2320/35
摘要： The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided.
-
4.发明申请RNAI-MEDIATED INHIBITION OF GREMLIN FOR TREATMENT OF IOP-RELATED CONDITIONS 审中-公开用于治疗与眼压有关的病症的RNAI介导的GREMLIN抑制剂公开(公告)号：US20120077864A1
公开(公告)日：2012-03-29
申请号：US13281785
申请日：2011-10-26
申请人： Jon E. Chatterton , Abbot F. Clark
发明人： Jon E. Chatterton , Abbot F. Clark
IPC分类号： A61K31/713 , A61P27/02 , A61P27/06 , A61K31/7105
CPC分类号： A61K31/7105 , C12N15/1136 , C12N2310/14
摘要： RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
摘要翻译： 提供了RNA干扰，用于抑制眼内压相关病症中的白蛋白，包括高眼压症和青光眼，如正常眼压青光眼和开角型青光眼。
-
5.发明授权RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions 有权RNAi介导的脾脏酪氨酸激酶相关炎症状态的抑制公开(公告)号：US08048863B2
公开(公告)日：2011-11-01
申请号：US12296621
申请日：2007-04-13
CPC分类号： C12N15/1137 , A61K31/7105 , A61K31/713 , C07H21/02 , C12N15/113 , C12N2310/14 , C12N2310/531 , C12N2320/30
摘要： RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
摘要翻译： 提供RNA干扰用于抑制脾脏酪氨酸激酶（Syk）mRNA表达，特别是用于治疗患有Syk相关炎性病症的患者或具有发展Syk相关炎性病症如过敏性结膜炎，眼部炎症，皮炎， 鼻炎，哮喘，过敏或肥大细胞疾病。
-
6.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA 审中-公开用于治疗乳腺癌的TNFα信号通路的RNAi相关性抑制公开(公告)号：US20110190376A1
公开(公告)日：2011-08-04
申请号：US13031358
申请日：2011-02-21
IPC分类号： A61K31/7105 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有或有发生黄斑水肿风险的患者。
-
7.发明申请公开(公告)号：US20110124708A1
公开(公告)日：2011-05-26
申请号：US12967121
申请日：2010-12-14
IPC分类号： A61K31/713 , A61P27/02 , A61P9/12
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; 1和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
8.发明授权RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma 有权RNAi介导的卷曲相关蛋白-1抑制治疗青光眼公开(公告)号：US07947660B2
公开(公告)日：2011-05-24
申请号：US11373376
申请日：2006-03-10
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/351
摘要： RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
摘要翻译： 提供RNA干扰用于抑制卷曲相关蛋白-1 mRNA表达，特别是用于治疗患有青光眼或有发展青光眼风险的患者。
-
公开(公告)号：US07790404B2
公开(公告)日：2010-09-07
申请号：US10222772
申请日：2002-08-16
IPC分类号： G01N33/566 , C07K14/705
CPC分类号： C07K14/70571 , C07H21/04
摘要： The invention provides isolated N-methyl-D-aspartate type 3B (NR3B) polypeptides, functional fragments and peptides, encoding nucleic acid molecules and polynucleotides, and specific antibodies. Also provided are excitatory glycine receptors, containing either NR3B or NR3A polypeptides. Further provided are methods for detecting excitatory glycine receptor ligands, agonists and antagonists. The invention also provides related diagnostic and therapeutic methods.
摘要翻译： 本发明提供分离的N-甲基-D-天冬氨酸3B型（NR3B）多肽，功能片段和肽，编码核酸分子和多核苷酸以及特异性抗体。 还提供了含有NR3B或NR3A多肽的兴奋性甘氨酸受体。 还提供了检测兴奋性甘氨酸受体配体，激动剂和拮抗剂的方法。 本发明还提供了相关的诊断和治疗方法。
-
10.发明申请公开(公告)号：US20100144844A1
公开(公告)日：2010-06-10
申请号：US12706014
申请日：2010-02-16
IPC分类号： A61K31/713 , A61P35/00 , A61P27/00 , A61K31/7105
CPC分类号： C12N15/1136 , A61K9/0048 , A61K31/7105 , A61K31/713 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/30 , C12N2320/31
摘要： RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
摘要翻译： 提供RNA干扰用于抑制HIF1A mRNA表达，用于治疗眼血管发生的患者，特别是用于治疗视网膜水肿，糖尿病性视网膜病变，与视网膜缺血相关的后遗症，后段新生血管形成（PSNV）和新生血管性青光眼，并用于治疗患有风险的患者 发展这样的条件。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.031 秒)
